uniQure has announced that they will move forward with the Phase I/II Clinical Trial of AMT-130, a gene therapy candidate for treatment of HD administered in a single dose to deep brain tissues with MRI-guided neurosurgical delivery. After careful review of safety data for the first enrolled cohort of ten patients, the independent Data Safety Monitoring Board has recommended continued dosing in the study. uniQure will now begin to recruit patients for a higher-dose cohort of the study to continue evaluating the safety, tolerability, and efficacy of AMT-130.
